Johnson & Johnson has announced the selection of a lead Covid-19 vaccine candidate with an expansion of its existing partnerships between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority. The company expects to start human trials of the vaccine by September this year, joining for more is Ludovic de Beaucoudrey, Medical Affairs Director at Janssen South Africa.